Nuvation Bio Inc.

NYSE:NUVB Stock Report

Market Cap: US$902.0m

Nuvation Bio Management

Management criteria checks 2/4

Nuvation Bio's CEO is David Hung, appointed in Apr 2018, has a tenure of 6.67 years. total yearly compensation is $4.32M, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 17.61% of the company’s shares, worth $158.87M. The average tenure of the management team and the board of directors is 2.4 years and 1.5 years respectively.

Key information

David Hung

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage13.7%
CEO tenure6.7yrs
CEO ownership17.6%
Management average tenure2.4yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?

Nov 20
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?

Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market

Oct 21

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

Aug 08

Is Nuvation Bio (NYSE:NUVB) A Risky Investment?

Aug 07
Is Nuvation Bio (NYSE:NUVB) A Risky Investment?

Nuvation Bio: A Potentially Transformative Acquisition

Jun 20

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate

Mar 31

Nuvation: Cash Is King, Science Is An Afterthought

Oct 03

We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth

Sep 14
We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth

Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit

Feb 14

We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely

Feb 10
We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely

We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth

Nov 09
We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth

Nuvation Bio GAAP EPS of -$0.12 beats by $0.02

Nov 03

CEO Compensation Analysis

How has David Hung's remuneration changed compared to Nuvation Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$532m

Jun 30 2024n/an/a

-US$511m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$4mUS$593k

-US$76m

Sep 30 2023n/an/a

-US$83m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$105m

Dec 31 2022US$8mUS$570k

-US$104m

Sep 30 2022n/an/a

-US$108m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$88m

Dec 31 2021US$5mUS$550k

-US$87m

Sep 30 2021n/an/a

-US$75m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$1mUS$475k

-US$42m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$33m

Dec 31 2019US$364kUS$218k

-US$34m

Compensation vs Market: David's total compensation ($USD4.32M) is above average for companies of similar size in the US market ($USD3.30M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Hung (66 yo)

6.7yrs

Tenure

US$4,324,280

Compensation

Dr. David T. Hung, M.D., serves as Founder, President, Chief Executive Officer and Director at Nuvation Bio Inc since April 2018 and has been it's Chairman of the Board since September 03, 2024. He founded...

Leadership Team

NamePositionTenureCompensationOwnership
David Hung
Founder6.7yrsUS$4.32m17.61%
$ 158.9m
Gary Hattersley
Chief Scientific Officer5.5yrsUS$1.36m0%
$ 0
David Liu
Chief Medical Officer2.4yrsUS$1.34m0.0027%
$ 24.1k
Philippe Sauvage
Chief Financial Officer & Principal Financial Officerless than a yearno datano data
Moses Makunje
VP of Finance and Principal Accounting & Financial Officer1.1yrsno data0.0032%
$ 28.4k
Stephen Dang
VP of Legal & Secretaryno datano datano data
Stacy Markel
Chief People Officer5.2yrsno data0.0032%
$ 28.4k
David Hanley
Chief Technical Operations Officer3.5yrsUS$3.31m0.0036%
$ 32.2k
Kerry Wentworth
Chief Regulatory Officer2.4yrsno datano data
Colleen Sjogren
Chief Commercial Officerless than a yearno data0.0074%
$ 67.0k
Junyuan Wang
CEO & Co-Founder of AnHeart Therapeutics and Directorless than a yearno data1.82%
$ 16.4m

2.4yrs

Average Tenure

54yo

Average Age

Experienced Management: NUVB's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Hung
Founder6.7yrsUS$4.32m17.61%
$ 158.9m
Junyuan Wang
CEO & Co-Founder of AnHeart Therapeutics and Directorless than a yearno data1.82%
$ 16.4m
Kathryn Falberg
Independent Director4.2yrsUS$447.77k0.074%
$ 670.0k
Kim Blickenstaff
Independent Director5.3yrsUS$440.35k0.051%
$ 461.5k
Gordon Mills
Member of Scientific Advisory Board1.5yrsno datano data
William Vernon
Independent Director5.5yrsUS$448.68k0.090%
$ 815.0k
Joyce O'Shaughnessy
Member of Scientific Advisory Board1.5yrsno datano data
Mansoor Mirza
Member of Scientific Advisory Board1.5yrsno datano data
Robert Bazemore
Lead Independent Director4.4yrsUS$442.60kno data
Allyson Ocean
Member of Scientific Advisory Board1.5yrsno datano data
Johann de Bono
Member of Scientific Advisory Board1.5yrsno datano data
Wassim Abida
Member of Scientific Advisory Board1.5yrsno datano data

1.5yrs

Average Tenure

63yo

Average Age

Experienced Board: NUVB's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nuvation Bio Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Clarence PowellBMO Capital Markets Equity Research
Robert BurnsH.C. Wainwright & Co.
Michael YeeJefferies LLC